GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Ending Cash Position

MedMira (MedMira) Ending Cash Position : $0.64 Mil (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Ending Cash Position?

MedMira's Ending Cash Position for the quarter that ended in Jan. 2024 was $0.64 Mil.

MedMira's quarterly Ending Cash Position increased from Jul. 2023 ($0.01 Mil) to Oct. 2023 ($0.65 Mil) but then declined from Oct. 2023 ($0.65 Mil) to Jan. 2024 ($0.64 Mil).

MedMira's annual Ending Cash Position increased from Jul. 2021 ($0.00 Mil) to Jul. 2022 ($0.03 Mil) but then declined from Jul. 2022 ($0.03 Mil) to Jul. 2023 ($0.01 Mil).


MedMira Ending Cash Position Historical Data

The historical data trend for MedMira's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Ending Cash Position Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.30 - 0.03 0.01

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.06 0.01 0.65 0.64

MedMira Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

MedMira's Ending Cash Position for the fiscal year that ended in Jul. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.026+-0.016
=0.01

MedMira's Ending Cash Position for the quarter that ended in Jan. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.664+-0.028
=0.64


MedMira Ending Cash Position Related Terms

Thank you for viewing the detailed overview of MedMira's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

Progress Update on Securities

By ACCESSWIRE 08-31-2023